<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Amelia Lorensia</style></author><author><style face="normal" font="default" size="100%">Rivan Virlando Suryadinata</style></author><author><style face="normal" font="default" size="100%">Dita Sukmaya Prawitasari</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Knowledge and Perception of the Risk of Respiration Disorders in COVID-19 Pandemic in COPD Patient: A Mixed-Method Study</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">COPD</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">knowledge</style></keyword><keyword><style  face="normal" font="default" size="100%">Perception.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">October 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">801-810</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; Chronic obstructive pulmonary disease (COPD) have a higher risk for COVID-19-related complications. Knowledge and perception will greatly influence the behavior of a COPD patient in dealing with a problem, such as the risk of COVID-19 infection. The purpose of the study was to determine knowledge and perceptions about the risk of respiration disorders during the COVID-19 pandemic in COPD patients. This research was a mixed methods research with an explanatory sequential research design. The location was conducted in Rungkut District in Surabaya City, East Java, from May-October 2022. Sampling by purposive sampling method, and analyzed descriptively. The research sample was 116 people. On the knowledge, the most correct answers were the COVID-19 virus was contagious (112 of 116). On the perception, the answer with the most positive level is a question regarding the use of masks. Some respondents had a low knowledge category (54 of 116), and the most positive perception category (57 of 116). The respondents' knowledge of the COVID-19 virus showed COVID-19 virus was a contagious disease and was transmitted through air. But many respondents didn’t know about the type of COVID-19 virus. Therefore, it was necessary to develop a strategy to increase knowledge about COVID-19 and related COPD treatment.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><section><style face="normal" font="default" size="100%">801</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Amelia Lorensia&lt;sup&gt;1,*&lt;/sup&gt;, Rivan Virlando Suryadinata&lt;sup&gt;2&lt;/sup&gt;, Dita Sukmaya Prawitasari&lt;sup&gt;3&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Faculty of Pharmacy, University of Surabaya, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Faculty of Medicine, University of Surabaya, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Faculty of Medicine, University of Surabaya, Indonesia.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Adyan Donastin</style></author><author><style face="normal" font="default" size="100%">Muhammad Amin</style></author><author><style face="normal" font="default" size="100%">Yulistiani</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mechanism of High Dosage Vitamin D Supplementation on The Lung Function and Quality of Life of Stable COPD Patients</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">6MWT</style></keyword><keyword><style  face="normal" font="default" size="100%">COPD</style></keyword><keyword><style  face="normal" font="default" size="100%">FEF25-75</style></keyword><keyword><style  face="normal" font="default" size="100%">FEV1</style></keyword><keyword><style  face="normal" font="default" size="100%">FVC</style></keyword><keyword><style  face="normal" font="default" size="100%">HDAC2</style></keyword><keyword><style  face="normal" font="default" size="100%">MDA</style></keyword><keyword><style  face="normal" font="default" size="100%">MMP-9</style></keyword><keyword><style  face="normal" font="default" size="100%">Nrf2</style></keyword><keyword><style  face="normal" font="default" size="100%">Oxidative stress</style></keyword><keyword><style  face="normal" font="default" size="100%">QOL.</style></keyword><keyword><style  face="normal" font="default" size="100%">Vitamin D</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">274-278</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Oxidative stress results from the amplification mechanism of COPD, which leads to decreased lung function and the quality of life of the sufferers. Vitamin D has a function in reducing oxidative stress levels through several mechanisms, which can be revealed by analyzing several biomarkers to determine the role of vitamin D on lung function and the quality of life of stable COPD patients. &lt;strong&gt;Methods: &lt;/strong&gt;The subjects included GOLD 2 and 3 stable COPD patients who had 25(OH)D levels of &amp;lt; 32 ng/ml and were receiving bronchodilator Indacaterol maleate therapy. The biomarkers examined included Nrf2, HDAC2, MDA, MMP-9, pulmonary function tests 6MWT, and QOL. The patients in the control and treatment groups were administered with vitamin D at a dose of 1,000 and 5,000 IU, respectively, for three months.&lt;strong&gt; Results:&lt;/strong&gt; The administration of vitamin D to the patients in the control and treatment groups can significantly reduce oxidative stress, as evidenced by reduced MDA (p-value &amp;lt; 0.01) and MMP-9 levels (p-value &amp;lt; 0.01). Vitamin D affects exercise tolerance, as evidenced by 6MWT (p-value = 0.01). Vitamin D affects the quality of life, as evidenced by 6MWT (p-value = 0.01). Vitamin D affects Nrf2 levels (p-value = 0.08) and HDAC2 (p-value = 0.01). &lt;strong&gt;Conclusion: &lt;/strong&gt;The pathway analysis through the study of the Nrf2, HDAC2, MMP-9, and MDA levels does not prove that vitamin D can prevent decreased lung function and quality of life in patients with stable COPD.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Original Article </style></work-type><section><style face="normal" font="default" size="100%">274</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Adyan Donastin&lt;sup&gt;1&lt;/sup&gt;, Muhammad Amin&lt;sup&gt;2,*&lt;/sup&gt;, Yulistiani&lt;sup&gt;3&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sub&gt;1&lt;/sub&gt;Doctoral-Level Medical Science Study Program, Faculty of Medicine, Airlangga University, Surabaya, INDONESIA; Faculty of Medicine, Nahdhatul Ulama Surabaya University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Pulmonology and Respiratory Medicine, Faculty of Medicine, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;3&lt;/sup&gt;Faculty of Pharmacy, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yothin Pothasak</style></author><author><style face="normal" font="default" size="100%">Jirakrit Leelarungrayub</style></author><author><style face="normal" font="default" size="100%">Surapol Natakankitkul</style></author><author><style face="normal" font="default" size="100%">Supawatchara Singhatong</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prototype Star Fruit-Honey Product and Effectiveness on Antixidants, Inflammation and Walking Distance in Participants with Stable Chronic Obstructive Pulmonary Disease (COPD)</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">6MWD</style></keyword><keyword><style  face="normal" font="default" size="100%">Antioxidant</style></keyword><keyword><style  face="normal" font="default" size="100%">COPD</style></keyword><keyword><style  face="normal" font="default" size="100%">Oxidative stress</style></keyword><keyword><style  face="normal" font="default" size="100%">Star fruit product</style></keyword><keyword><style  face="normal" font="default" size="100%">TNF-∝</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">August 2020</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><pages><style face="normal" font="default" size="100%">1121-1134</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Star fruit (&lt;em&gt;Averrhoa carambola &lt;/em&gt;L.) is a seasonal fruit, which has proven antioxidant and inflammation activities&lt;em&gt; in vitro&lt;/em&gt;. However, sweet-type is more available than sour-type. Therefore, developing a new product from sweet-type star fruit, and evaluating its effectiveness on antioxidants and inflammation have been very challenging.&lt;strong&gt; Objectives: &lt;/strong&gt;The aims were to develop a prototype product from sweet-type star fruit and evaluate its effectiveness with or without walking exercise on participants with stable chronic obstructive pulmonary disease (COPD). &lt;strong&gt;Methods:&lt;/strong&gt; The prototype product of sweet-type star fruit was prepared industrially by mixing with honey before nutrients such as L-ascorbic acid (Vit C) and total phenolic compound, and contaminants like chemicals, microbials and oxalic acid were evaluated. Effectiveness of this product on antioxidents, inflammation and physical function was evaluated in participants with stable COPD with and without walking exercise, and compared to walking exercise and control participants. Two spoons of the product (20 g) in sterile warm water (150 mL) were guided and consumed twice daily for 4 weeks, whereas the walking exercise was prescribed with moderate intensity at home for 30 min 3 days per week. Plasma Vit C, total antioxidant capacity (TAC), malondialdehyde (MDA), tumor necrotic factoralpha (TNF-∝) and 6-minutes walking distance (6MWD) were evaluated before and after the 4-week study period. &lt;strong&gt;Results: &lt;/strong&gt;The prototype product composed of star fruit juice with honey (1:1, v:v). Main nutrients were composed of ash (0.4 g), carbohydrate (74.59 g), lipid (2.88 g), protein (0.57 g) and 326.56 kcal of total energy, whereas Vit C and total phenolic compound were equivalent to 0.25 ± 0.11 mg and 144.89 ± 2.51 μg gallic acid equivalent in a 100 gram of product. The results of chemicals and microbials showed safety under food conditions. The results of study compared the ages of stable COPD participants between those of the controls (n=10, 69.20±1.40 years), and those with star fruit juice and honey supplement (n=20, 71.25 ± 6.01 years), walking exercise (n=15, 60.60±3.38 years), and supplement with walking exercise (n=15, 64.40±1.63 years) and no statistical difference was shown in any parameters in the control group. Whereas, the plasma Vit C and TAC levels increased, and MDA and TNF-∝ levels reduced significantly, in the supplement consumption group, which was in contrast to the Vit C, MDA and TNF-∝ levels in the walking exercise group. However, the TAC level increased significantly when the walking exercise was completed. When the prototype product was applied to the walking exercise, the levels of Vit C and TAC increased, and MDA and TNF-∝ levels reduced significantly. Whereas, the supplement levels increased significantly in all of the groups, especially in the 6MWD. &lt;strong&gt;Conclusion:&lt;/strong&gt; This study proposed that sweet-type star fruit can be prepared industrially by mixing with honey, and be developed as a new commercial product with antioxidant and inflammation activities for participants suffering with chronic lung disease.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">1121</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Yothin Pothasak&lt;sup&gt;1&lt;/sup&gt;, Jirakrit Leelarungrayub&lt;sup&gt;1,&lt;/sup&gt;*, Surapol Natakankitkul&lt;sup&gt;2&lt;/sup&gt;, Supawatchara Singhatong&lt;sup&gt;3 &lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Physical Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Pharmaceutical Science, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Division of Clinical Chemistry, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, THAILAND.&lt;/p&gt;
</style></auth-address></record></records></xml>